Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.
6don MSN
Regeneron targets $7B in U.S. manufacturing investment as R&D and commercial launches accelerate
Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...
StockStory.org on MSN
REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage
Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Dupixent had the most impressions and largest impressions share of voice (SOV) among Rx and over-the-counter (OTC) brands in March, according to data released by iSpot.tv Monday evening. This is a ...
Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...
Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback